Nikhil Munshi, MD, on Final Data on Cilta-Cel in Multiple Myeloma From CARTITUDE-1

“The take home message is that CAR T-cells are extremely effective. The toxicity is manageable and so, its utilization in our patients, even in elderly patients, should become an important component of therapeutic management... I do see CAR T-cell probably aspart of a combined immunotherapy approach CAR T-cells and bispecificimmunomodulators are going to become standard of treatment, and most likely curative treatment in myeloma.”

A final analysis of the phase 1b/2 CARTITUDE-1 trial (NCT03548207) of the approved chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti; Janssen) in patients with relapsed/refractory multiple myeloma was presented at the European Hematology Association (EHA) 2023 Congress, held June 8-11, both virtually and in Frankfurt, Germany, by Nikhil Munshi, MD, director, Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center; Kraft Family Chair, director of Multiple Myeloma Immune Effector Cell Therapy, senior physician at Dana-Farber Cancer Institute; and a professor of Medicine at Harvard Medical School.

CGTLive™’s sister site, OncLive™, spoke with Munshi while at EHA to learn more about the updated data and the continued efficacy seen with cilta-cel since its 2022 approval. He also went over the study population and the favorable safety profile observed. Munshi shared his thoughts about the future outlook with CAR T-cell therapy and multiple myeloma, including bringing up the use of CAR T-cell therapy into earlier lines of treatment and combining modes of treatment such as bispecific antibodies with CAR T-cell therapy.

Click here for more coverage of EHA 2023.

REFERENCE

Munshi N, Martin T, Usmani SZ, et al. CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma. Presented at: EHA 2023 Congress. Abstract S202